Page 251 - Medicinal Chemistry Self Assessment

240 Medicinal Chemistry Self Assessment

Dihydropyridine calcium channel blocker, Fluvoxamine metabolites, 53, 171 I
30, 134 Functional groups, 3-9, 11, 95-98, 99
Diltiazem, 9, 103 Ibuprofen, 4, 96
Dipeptidyl peptidase IV, 83, 223 G Imipramine analogs, 5, 97
Dipole-dipole interaction, 202 GABA , 71, 72, 199, 201, 203 Inactive metabolite, 63, 186-187
A
D-Phe-Pro-Arg tripeptide sequence, 43-45, Gemfibrozil, 47-49, 165-168 Inactive product, 58-59, 179
159-163 Induction, 4, 55, 79, 96, 173-174, 217
Geometric isomer(s), 21, 28, 52, 62, 92,
Drug action 117-119, 130-131, 170, 184, 235 Inosinic acid, 20, 116
duration, 60, 181 GI drug absorption compartments, 36, 145 Insulin, 62, 185
stereochemistry and, 21-22, 117-121 Glucocorticoid, 57-58, 177-178 structure, 14, 111
Drug binding interactions, 17-20, 113-116 Glucuronide conjugation, 53, 92, 172, 237 Interactions, 62, 185
Drug interaction, 32, 139 Glutamate, 20, 116 Intermediate-acting agent, 71, 200
Drug metabolism, 23-24, 123-125 Glutamic acid, 20, 79, 116, 218 Intestine pH, 14, 109
E Glutamine, 98 Ion channels, 20, 116
Ion-dipole interaction(s), 19, 58, 62, 115,
Glyburide, 42, 158
E-geometric isomer, 170 metabolite, 42, 158 185, 178
Electron donation, 4, 55, 79, 96, 173, 217 Gram (-) activity, 35, 143 Ionic bond, 202
Electron withdrawing, 4, 55, 79, 96, 97, Gram (+) activity, 35, 143 Ionic interaction, 62, 185
173-174, 217 Ionization percentage, 12, 106-108
Green pepper flavor, 20, 116
Elimination, 48, 167 Ionized, 31, 36, 55, 69, 71, 75-76, 91, 137,
Guanidine functional group, 8, 102 145, 174, 193-194, 201, 211-212, 233
half-life, 49, 168
unchanged, 70, 197 H Irbesartan, 13-14, 109
Embeconazole, 15, 111-112 Half-life, 42, 156 Isoleucine, 87, 227
Enantiomer(s), 21-22, 52, 62, 92, 117-121, L
170, 184, 235 Halogenated aromatic hydrocarbon, 185
Enterohepatic recycling, 23, 123, 124 Haloperidol, 55-56, 173-176 Leu-Val peptide bond, 30, 134
Enzymatic hydrolysis, 147 Henderson-Hasselbalch equation, 12, Levothyroxine (T ), 61-63, 183-187
4
106-107, 108, 155
Epimer, 92, 235 metabolites, 63, 186
Hepatic metabolism, 70, 197
Ester hydrolysis, 79-80, 218-219 Hepatic oxidation, 53, 172 Lidocaine, 65-67, 189-192
Estradiol, 21, 23, 117-119, 123 Sodium channel blocker, 65, 189-192
Heroin, 23, 123 Lipid solubility, 31, 138, 195
Estrogen, 62, 185 Histidine, 79, 218
Ether, 185 HMG CoA reductase, 74, 207-209 Lipid soluble esters, 174
Ezetimibe, 11, 105-106 Lipophilic absorption, 66, 190
HMG-CoA reductase inhibitor, 22, 119-120 Lipophilic ester, 60, 180-181
F Hormone replacement therapy, 62, 184 Lisinopril, 17, 113
Hydrochloride monohydrate salt, 89, 231 Lomitapide, 9, 103
Fenofibrate, 47-49, 165-168 Hydrochloride salt, 13-14, 109
as active drug, 48, 166 Long-acting agent, 71, 200
Hydrocortisone, 57-60, 177-181 Loperamide, 14, 109-110
as prodrug, 48, 166
Hydrogen bond(s), 18-19, 58, 62, 88-89, Lorazepam, 53, 172
Fesoterodine, 18, 114, 115 115, 178, 185, 195, 202, 207, 228
Fibrin, 43, 159 Hydrolysis, 56, 70, 92, 176, 198, 236 Losartan, 32, 41, 139, 153
Fibrinogen, 43, 159 Hydrolytic reactions, 44, 161-162 L-tyrosine, 62, 185-186
Flavors, 20, 116 Hydrolyzable peptide bond, 30, 134 M
Fluvastatin, 22, 73-74, 119-120, 205-209 Hydrophilic reaction, 4, 55, 73, 75, 79, 96,
conformationally restricted analog of, 173, 205, 211, 217 Maleate salt, 52, 170-171
74, 208-209 Hydrophobic reaction, 4, 19, 55, 62-63, Mechanism of action, 42, 155-156
Fluvoxamine, 24, 51-53, 125, 169-172 73, 75, 79, 88-89, 96, 114-115, 173, Metabolic transformation, 28-29, 53, 77-78,
metabolites, 53, 171 185-186, 196, 202, 205, 211, 217, 171-172, 214-215
Fluvoxamine + alprazolam, 53, 172 228, 231 Metabolites, 24, 124
Hydroxyzine, 39-40, 149-152 Methionine, 89, 230
Fluvoxamine + lorazepam, 53, 172